Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | STING1 | Q86WV6 | 7/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL761670 | 1.00 | RAB9A (0.43) | RAB9ANPC1TSHRHDAC4PTGS2 | |
| SCHEMBL19997585 | 1.00 | RAB9A (0.43) | RAB9ANPC1TSHRHDAC4PTGS2 | |
| SCHEMBL17558083 | 1.00 | RAB9A (0.43) | RAB9ANPC1TSHRHDAC4PTGS2 | |
| SCHEMBL19997586 | 1.00 | RAB9A (0.43) | RAB9ANPC1TSHRHDAC4PTGS2 | |
| SCHEMBL17558067 | 0.91 | TSHR (0.42) | RAB9ANPC1TSHRPTGS2ALDH1A1 | |
| SCHEMBL19632888 | 0.89 | TSHR (0.42) | RAB9ANPC1TSHRHDAC4PTGS2 | |
| SCHEMBL1755657 | 0.89 | RAB9A (0.40) | RAB9ANPC1TSHRHDAC4PTGS2 | |
| SCHEMBL19795842 | 0.83 | ALDH1A1 (0.34) | RAB9ANPC1TSHRALDH1A1HTT | |
| SCHEMBL764381 | 0.81 | RAB9A (0.35) | RAB9ANPC1TSHRHDAC4PTGS2 | |
| SCHEMBL764383 | 0.79 | NPC1 (0.34) | RAB9ANPC1TSHRHDAC4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697644-B2 | Process for synthesis of eliglustat and intermediate compounds thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2023-07-11 | — | — | US | disclosed |
| US-11697644-B2 | Process for synthesis of eliglustat and intermediate compounds thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2023-07-11 | — | — | US | disclosed |
| US-20210171507-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2021-06-10 | — | — | US | disclosed |
| EP-3611171-A1 | METHOD FOR SYNTHESIS OF ELIGLUSTAT AND INTERMEDIATE COMPOUNDS THEREOF | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2020-02-19 | — | — | EP | disclosed |
| US-20200031808-A1 | PROCESS FOR SYNTHESIS OF ELIGLUSTAT AND INTERMEDIATE COMPOUNDS THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2020-01-30 | — | — | US | disclosed |
| WO-2020020365-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE ELIGLUSTAT | 中国医学科学院药物研究所 | 2020-01-30 | — | — | WO | disclosed |
| US-20190322649-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2019-10-24 | — | — | US | disclosed |
| US-9988364-B1 | Process for synthesis of Eliglustat and intermediate compounds thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-9988364-B1 | Process for synthesis of Eliglustat and intermediate compounds thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-20170334888-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2017-11-23 | — | — | US | disclosed |
| US-8779163-B2 | Synthesis of UDP-Glucose: N-acylsphingosine glucosyl transferase inhibitors | GENZYME CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120296088-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYL TRANSFERASE INHIBITORS | GENZYME CORPORATION | 2012-11-22 | — | — | US | disclosed |
| US-8138353-B2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110003987-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-7763738-B2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-7615573-B2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080058514-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | HIRTH BRADFORD H | 2008-03-06 | — | — | US | disclosed |
| US-7265228-B2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070203223-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2007-08-30 | — | — | US | disclosed |
| US-7196205-B2 | Synthesis of amino ceramide-like compounds; for treating Tay-Sachs, Gaucher's or Fabry's disease; amenable to large scale preparations | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120296088-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYL TRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | RAB9A 1515/4885NPC1 129/4885TSHR 4390/4885 |
| US-20210171507-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | RAB9A 1520/4885NPC1 137/4885TSHR 4491/4885 |
| US-20170334888-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | RAB9A 1520/4885NPC1 137/4885TSHR 4491/4885 |
| US-11697644-B2 | Process for synthesis of eliglustat and intermediate compounds thereof | EPOR, FGFR1, ABL1 | RAB9A 439/4885NPC1 1215/4885TSHR 2762/4885 |
| US-20110003987-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | RAB9A 1520/4885NPC1 137/4885TSHR 4491/4885 |
| US-20080058514-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | RAB9A 1520/4885NPC1 137/4885TSHR 4491/4885 |
| US-20190322649-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | RAB9A 1520/4885NPC1 137/4885TSHR 4491/4885 |
| US-20070203223-A1 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | UGCG, UGGT1, DPAGT1 | RAB9A 1520/4885NPC1 137/4885TSHR 4491/4885 |
| US-20200031808-A1 | PROCESS FOR SYNTHESIS OF ELIGLUSTAT AND INTERMEDIATE COMPOUNDS THEREOF | COASY, ELL, CYP3A4 | RAB9A 794/4885NPC1 1518/4885TSHR 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.